Publications by authors named "Simone Celant"

Claim this Profile
T
Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries.
Massimo Breccia, Simone Celant, Francesca Palandri, Francesco Passamonti, Pier Paolo Olimpieri

Ann Hematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries.
Massimo Breccia, Simone Celant, Francesca Palandri, Francesco Passamonti, Pier Paolo Olimpieri

Br J Haematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study.
Gian Matteo Rigolin, Pier Paolo Olimpieri, Valentina Summa, Simone Celant, Lydia Scarfò

Hemasphere· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Withdrawal notice to .
Maria Lucia Iacovino, Simone Celant, Luca Tomassini, Laura Arenare, Andrea Caglio

Lancet Reg Health Eur· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].
Maria Lucia Iacovino, Simone Celant, Luca Tomassini, Laura Arenare, Andrea Caglio

Lancet Reg Health Eur· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].
Maria Lucia Iacovino, Simone Celant, Luca Tomassini, Laura Arenare, Andrea Caglio

Lancet Reg Health Eur· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study.
Maria Lucia Iacovino, Simone Celant, Luca Tomassini, Laura Arenare, Andrea Caglio

Lancet Reg Health Eur· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.
Marcello Arca, Simone Celant, Pier Paolo Olimpieri, Antonietta Colatrella, Luca Tomassini

J Am Heart Assoc· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study.
Carlo Torti, Pier Paolo Olimpieri, Paolo Bonfanti, Carlo Tascini, Simone Celant

Lancet Reg Health Eur· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency.
Gian Matteo Rigolin, Pier Paolo Olimpieri, Valentina Summa, Simone Celant, Lydia Scarfò

Blood Cancer J· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA).
Massimo Breccia, Pier Paolo Olimpieri, Simone Celant, Odoardo Maria Olimpieri, Fabrizio Pane

Ann Hematol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry.
Bruno Vincenzi, Andrea Napolitano, Alessandro Comandone, Roberta Sanfilippo, Simone Celant

Int J Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of chronic myeloid leukaemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA).
Massimo Breccia, Pier Paolo Olimpieri, Simone Celant, Odoardo Olimpieri, Fabrizio Pane

Br J Haematol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the COVID-19 pandemic on prescription of sacubitril/valsartan in Italy.
Giuseppe M C Rosano, Simone Celant, Pier Paolo Olimpieri, Antonietta Colatrella, Graziano Onder

Eur J Heart Fail· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy.
Pierluigi Russo, Evelina Tacconelli, Pier Paolo Olimpieri, Simone Celant, Antonietta Colatrella

Viruses· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Under-prescription of direct oral anticoagulants for treatment of non-valvular atrial fibrillation and venous thromboembolism in the COVID-19 lockdown period.
Graziano Onder, Pier Paolo Olimpieri, Simone Celant, Andrea Di Lenarda, Giuseppe Ambrosio

Eur J Prev Cardiol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis.
Giovanni Palladini, Simone Celant, Paolo Milani, Valentina Summa, Giovanni Affronti

Leuk Lymphoma· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA).
Massimo Breccia, Simone Celant, Pier Paolo Olimpieri, Odoardo M Olimpieri, Fabrizio Pane

Ann Hematol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis